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Activating mutations in the epidermal growth factor receptor (EGFR) are found in approx-imately 10% to 15% of non–small-cell lung cancer (NSCLC) patients in the United 
States and up to 35% of those in East Asia.1,2 Patients with this mutation are more likely 
to be female, Asian, and nonsmokers than the general lung cancer population. For patients 
with these mutations, treatment with EGFR tyrosine kinase inhibitors (TKIs) erlotinib, afa-
tinib, or gefitinib is associated with higher response rates and improved progression-free sur-
vival (PFS) compared with standard platinum-based doublet chemotherapy.3,4 Unfortunately, 
acquired resistance to these TKIs inevitably develops. A variety of resistance mechanisms 
have been identified, including a secondary mutation in EGFR, T790M.5–7 Resistance to 
TKIs usually occurs at a median of 9 to 13 months after treatment initiation although there is 
a wide range. In this regard, some patients have progression of disease years after initiation 
of TKI therapy while others have rapid progression and widespread disease after only a few 
months. Currently, there are no reliable clinical tools to predict outcomes for patients with 
EGFR mutations treated with TKIs.
In this issue of the Journal of Thoracic Oncology, Keam et al. report on the relation 
between FDG-PET/CT metabolic parameters and outcomes in patients with EGFR-mutant 
lung cancer receiving gefitinib as first-line treatment at a single center in South Korea. 
Seventy-five patients with stage IIIB or IV chemotherapy naive NSCLC were identified 
from a retrospective database. All patients had one of the two most common activating 
EGFR mutations—either a deletion in exon 19 or the L858R missense mutation in exon 
21. Patients with these mutations are known to respond well to EGFR TKIs.1 Outcomes for 
patients enrolled on this trial were similar to historical controls, with an overall response 
rate of 69%, median PFS 11.5 months, and median overall survival (OS) 26.7 months.
Keam et al. performed whole-body FDG-PET/CT in all patients before initiation of 
therapy and found that total lesion glycolysis (TLG), a measure that reflects both tumor 
bulk and metabolic activity, was significantly associated with PFS and OS. Patients with the 
highest TLG had a PFS of only 7.2 months, compared with patients with low TLG with PFS 
24.2 months. SUVmax was also associated with PFS, but the correlation was not as strong, 
and there was no significant association between SUVmax and OS. Interestingly, response 
rates were not different between those with high TLG and those with low TLG.
Similar to many retrospective studies, the temporal performance of the imaging in 
the study by Keam et al. was not standardized and there was a large range between the 
FDG-PET/CT acquisition and the initiation of gefitinib therapy (range 0–46 days, median 
19 days). Because of the considerable variation of tumor metabolic activity at different time 
points, this inconsistency in the performance of the baseline FDG-PET/CT is a potential 
limitation of the applicability of the imaging analysis and conclusions drawn. In addition, 
in terms of methodology, the use of a single threshold (50% of SUVmax for each lesion) 
to determine volume is prone to error, primary due to the value being affected by lesion 
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size and lesion to background (L/B) ratio. This error is fur-
ther magnified when the lesions evaluated have a small size. 
Although lesion size and L/B ratio are not discussed by the 
investigators, more sophisticated approaches that take these 
factors into consideration are not generally available.
The results of the study by Keam et al. are interesting. 
However, the clinical applicability is currently somewhat limi-
ted. Even if it was possible to reliably identify patients likely 
to have shorter PFS on TKIs, it is not clear that treatment rec-
ommendations for these patients would change—erlotinib, 
gefitinib, and afatinib remain the agents of choice for patients 
with activating EGFR mutations. Also, this was a relatively 
small, single center study in Asian patients. Validation in a 
larger cohort, especially one incorporating patients from dif-
ferent geographic regions treated with different TKIs, would 
be helpful.
It is not surprising that patients with bulky, highly active 
lesions have poor outcomes compared with those patients 
with a small volume of disease. As the authors note, larger 
tumors may have more genetic heterogeneity; therefore, resis-
tant clones may be more likely to be present at baseline and 
may become clinically apparent more quickly. Patients such as 
those with high TLG who are known to have a relatively poor 
prognosis with standard treatment should be evaluated for clin-
ical protocols aiming to prevent emergence of resistant clones. 
Third generation EGFR inhibitors rociletinib and AZD9291 
appear to be active in EGFR-mutant NSCLC resistant to first-
line TKIs, especially in tumors with T790M resistance muta-
tions.8,9 Ongoing studies (NCT02186301, NCT02296125) are 
comparing these agents to erlotinib or gefitnib for treatment 
naive patients with EGFR-mutant NSCLC, in hopes that these 
newer agents may delay the emergence of resistance.
In summary, although significant strides have been made 
recently in the treatment of EGFR-mutant NSCLC, there is still 
work to be done. Keam et al. have contributed to this undertak-
ing by elucidating that high TLG can predict PFS and develop-
ment of gefitinib resistance in EGFR-mutant NSCLC patients 
treated with first-line gefitinib. Their study underlines the urgent 
need for new novel therapeutics, especially for those patients 
identified as having poor outcomes.
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